Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Investegate |NOVARTIS AG CHF0.50(REGD) Announcements | NOVARTIS AG CHF0.50(REGD): Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Novartis AG (via Public) / Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.
An oncologist reflects on two patients. One chose to stop cancer treatment rather than gain weight, and another found herself attracting unwanted admirers for extreme weight loss from terminal cancer.
Transgender and gender diverse youth need high-quality medical care just as other teenagers
The Endocrine Society and a coalition of LGBTQ+ youth and reproductive health organizations argued in a joint submission to the High Court of England and Wales that transgender teenagers should be able to give informed consent to treatment the same way teenagers with other medical conditions can.
The coalition submitted a written intervention as part of the appeal of Bell v Tavistock and Portman NHS Health Foundation, a case where the High Court ruled in December 2020 that adolescents younger than age 16 are not competent to give consent to treatment to delay puberty. The ruling threatens to block transgender and gender diverse teenagers from accessing the medical care they need.